查詢結果分析
相關文獻
- Risperidone在精神分裂症治療之劑量調整
- An Open Trial of Risperidone Shifting from Oral Form to Long-acting Injection Form in Patients with Schizophrenia
- Efficacy and Adverse Effects of Higher Dose Amphotericin B Monotherapy for Cryptococcal Meningitis in Patients with Advanced HIV Infection
- 廣泛性焦慮症患者Buspirone, Lorazepam與Diazepam治療雙盲試驗
- Buspirone和Lorazepam對泛焦慮症之臨床效用
- 精神分裂症患者之Haloperidol 快速鎮定治療:三種不同劑量之療效評估
- High-dose Quetiapine for the Treatment of Schizophrenia with Inadequate Response to Quetiapine 600 mg/day
- 精神分裂症治療之選藥原則
- 精神分裂患者使用Olanzapine與Risperidone之代謝性副作用評估
- 本院使用clozapine副作用之探討
頁籤選單縮合
題 名 | Risperidone在精神分裂症治療之劑量調整=Dosing Regiment of Risperidone in the Treatment of Patients with Schizophrenia |
---|---|
作 者 | 李志銘; 柯毅文; 陳登義; | 書刊名 | 臺灣精神醫學 |
卷 期 | 15:2 2001.06[民90.06] |
頁 次 | 頁42-49 |
分類號 | 418.21 |
關鍵詞 | 精神分裂症; 療效; 副作用; Risperidone; Schizophrenia; Efficacy; Safety; |
語 文 | 中文(Chinese) |
中文摘要 | 目的:本研究的目的在探討,新一代抗精神病藥物risperidone(每日2-16 mg)治療精神分裂症患者8週,對於活性症狀、負性症狀的臨床療效及安全性,以供日後臨床治療參考。方法:本研究為開放性臨床試驗,收集門診或住院病患診斷為精神分裂症患者,使用中文版活性及負性症狀評量表 (PANSS-CH)、臨床整體評量表 (CGI) 等評量表評估臨床療效,臨床療效之主要指標是以PANSS-CH總分之改善率 20%為反應良好與否之判準。以錐體外症狀評量表 (ESRS) 評估病患錐體外副作用,並且於每次訪視記錄病患副作用。結果:本試驗共收入25位病患。19 (76%) 位病患完成八週治療且完成評估,在CGI或PANSS-CH總分,於治療一週後評估就有統計上的差異;對於活性症狀 (PANSS-P)、負性症狀 (PANSS-N)、一般精神病理 (PANSS-G) 及攻擊危險度之補充項目 (PANSS-S),各別於治療二週後評估,皆有統計上的差異;八週後PANSS的總分改善率為27.1%,19位病患最終平均使用劑量每日4.36±1.32 mg,11 (57.9%) 位病患為反應良好者。ESRS總分數基準6.89±14.85,八週後,為5.10±8.79,兩者無統計上的差異。治療最常見副作用包括:頭暈、失眠、口水增加等。結論:risperidone對於多數精神分裂症病患具有明顯療效,而且病患耐受性佳。 |
英文摘要 | Objectives: The purpose of this study is to evaluate the clinical improvement of positive and negative symptoms and safety of atypical antipsychotic agent,-risperidone (daily dose of 2-16 mg) in treating schizophrenic patients for eight weeks. Methods: The is an 8-week, open study. Subjects were recruited either out-patients or hospitalized patients. Chinese PANSS (PANSS-CH) and CGI (Clinical Global Impression) were used to assess therapeutic effects. Primary efficacy defined as 20% mean changes from the baseline of overall PANSS-CH scores. ESRS (Extrapyramidal Symptoms Rating Scale) was used as the marker to assess the side effects of extrapyramidal symptoms; any other side effects were recorded during each visit. Results: There were 25 subjects enrolled in this study; of which, 19 subjects (76%) had completed the 8-week treatment and all the evaluations; there was a statistically significant difference from the first-week data of CGI & PANSS-CH; there were statistically significant differences in the second-week data of subscales- positive (PANSS-P), negative (PANSS-N), general psychopathology (PANSS-G) and supplement items for the aggression risk profile (PANSS-S) of PANSS-CH. Average score of rate of improvement in using PANSS-CH, in a period of 8 weeks was 27.1%, of 19 subjects, 11 of them (57.9%) showed good response, the final average dose per day was 4.36±1.32 mg. The average score of ESRS was 6.89±14.85 and change to 5.10 ±8.79 after 8 weeks, it showed no statistically significant difference. The most common side effects are dizziness, insomnia, salivation increases etc. Conclusion: In this study, risperidone not only show prominent therapeutic effects for most patients but are also well tolerated. |
本系統中英文摘要資訊取自各篇刊載內容。